Kyntra Bio (NASDAQ:KYNB) Stock Gets Price Target Reduction from HC Wainwright

Kyntra Bio (NASDAQ:KYNB – Free Report) had its target price lowered by HC Wainwright to $18.00 in a research report sent to investors on Tuesday,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Kyntra Bio’s Q4 2026 earnings at ($2.39) EPS and FY2027 earnings at ($7.02) EPS.

Several other research analysts have also recently commented on the stock. Maxim Group assumed coverage on shares of Kyntra Bio in a research report on Tuesday, October 13th. They issued a “buy” rating and a $35.00 target price for the company. Lake Street Capital assumed coverage on Kyntra Bio in a report on Thursday, September 17th. They set a “buy” rating and a $41.00 price target on the stock. Zacks Research raised Kyntra Bio from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 10th. Finally, Weiss Ratings downgraded Kyntra Bio from a “sell (d+)” rating to a “sell (d)” rating in a research report on Tuesday, November 10th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $25.20.

Check Out Our Latest Report on Kyntra Bio

Kyntra Bio Price Performance

Shares of KYNB opened at $1.83 on Tuesday. The firm has a fifty day moving average of $5.36 and a 200-day moving average of $6.75. Kyntra Bio has a 1 year low of $1.78 and a 1 year high of $10.47.

Hedge Funds Weigh In On Kyntra Bio

An institutional investor recently bought a new position in Kyntra Bio stock. Renaissance Technologies LLC purchased a new position in shares of Kyntra Bio Inc (NASDAQ:KYNB – Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 27,481 shares of the company’s stock, valued at approximately $186,000. Renaissance Technologies LLC owned approximately 0.68% of Kyntra Bio at the end of the most recent quarter. Institutional investors own 72.71% of the company’s stock.

About Kyntra Bio

(Get Free Report)

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

Recommended Stories

Analyst Recommendations for Kyntra Bio (NASDAQ:KYNB)

Receive News & Ratings for Kyntra Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyntra Bio and related companies with MarketBeat.com's FREE daily email newsletter.